Welcome to our dedicated page for Promis Neuroscie SEC filings (Ticker: PMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProMIS Neurosciences Inc. filings document a clinical-stage biotechnology issuer with common shares listed on the Nasdaq Capital Market and organized in Ontario, Canada. Formal disclosures cover PMN310 and related clinical or regulatory updates, operating results, financing arrangements, registered security status, and the company’s capital structure, including common shares, purchase warrants, pre-funded warrants, and share consolidation actions.
Proxy and 8-K filings record shareholder voting matters, director elections, independent auditor ratification, equity incentive plan proposals, board appointments, and other governance changes. The filing record also documents Nasdaq listing compliance matters, material definitive agreements, and financial condition disclosures connected to the company’s neurodegenerative-disease development programs.
On 21 Jul 2025 ProMIS Neurosciences (PMN) filed an 8-K disclosing two material items.
- ATM program terminated: The Company and BTIG mutually ended the US$25 m at-the-market agreement first signed 5 Jan 2024. Only 75,862 shares were sold for gross proceeds of US$190,274, leaving US$24.8 m unused. No termination penalties apply and no further shares will be issued under this facility.
- Pipeline progress: The FDA granted Fast Track Designation to PMN310, ProMIS’s lead monoclonal antibody for Alzheimer’s disease. A Data & Safety Monitoring Board has authorised escalation to the 10 mg/kg cohort in the ongoing Phase 1b trial, and, as of 21 Jul 2025, no amyloid-related imaging abnormalities (ARIA) have been observed.
The filing contains no financial results, but it removes potential equity dilution from the ATM, while regulatory momentum for PMN310 could shorten the development timeline.
On 21 Jul 2025 ProMIS Neurosciences (PMN) filed an 8-K disclosing two material items.
- ATM program terminated: The Company and BTIG mutually ended the US$25 m at-the-market agreement first signed 5 Jan 2024. Only 75,862 shares were sold for gross proceeds of US$190,274, leaving US$24.8 m unused. No termination penalties apply and no further shares will be issued under this facility.
- Pipeline progress: The FDA granted Fast Track Designation to PMN310, ProMIS’s lead monoclonal antibody for Alzheimer’s disease. A Data & Safety Monitoring Board has authorised escalation to the 10 mg/kg cohort in the ongoing Phase 1b trial, and, as of 21 Jul 2025, no amyloid-related imaging abnormalities (ARIA) have been observed.
The filing contains no financial results, but it removes potential equity dilution from the ATM, while regulatory momentum for PMN310 could shorten the development timeline.